Hims vs Hers vs Ro vs Found: GLP-1 Telehealth Compared (2026)
Hims, Hers, Ro, and Found are GLP-1 telehealth providers with different approaches to pricing, brand-name access, coaching, and clinical oversight. This four-way comparison lays the differences out side-by-side so you can match the right operator to your situation.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Hims
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Hers
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Ro
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Found
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Side-by-Side Comparison
| Attribute | Hims | Hers | Ro | Found |
|---|---|---|---|---|
| Primary Audience | Men 18+ | Women 18+ | Adults 18+ | Adults 18+ |
| Membership / Plan Fee | $39 first month, then $149/mo (medication extra) | $39 first month, then $149/mo (medication extra) | $39 first month, then $149/mo, or $74/mo prepaid annually (medication extra) | CORE $129/mo ($99/mo on a 6-month plan); GLP-1 medication extra |
| Brand-Name Medication Price | Wegovy pill and Foundayo from $149/mo; Wegovy pen from $199; Zepbound from $299 | Wegovy pill and Foundayo from $149/mo; Wegovy pen from $199; Zepbound from $299 | Insurance checked first; cash prices track manufacturer self-pay rates | Billed to insurance or paid separately |
| Compounded GLP-1 | Not listed on the weight-loss page (Oct 2026) | Not listed on the weight-loss page (Oct 2026) | Not listed on the weight-loss page (Oct 2026) | Not stated in plan terms |
| FDA Brand-Name GLP-1 Access | Wegovy (pen and pill), Foundayo, Ozempic, Zepbound, Mounjaro | Wegovy (pen and pill), Foundayo, Ozempic, Zepbound, Mounjaro | Wegovy (pen and pill), Foundayo, Ozempic, Zepbound | Wegovy, Zepbound, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza |
| Insurance Navigation | Limited | Limited | Yes — dedicated team | Yes — dedicated team |
| 1:1 Coaching | No | No | Optional add-on | Yes — included on Rx path |
| Adjacent Categories | ED, hair, mental health, primary care | Menopause, hair, skincare, sexual wellness | ED (Ro Sparks, Daily Rise), hair, primary care | GLP-1 only — with off-label adjuncts (metformin, bupropion-naltrexone) |
| Cancellation Terms | Cancel 2+ days before billing; first month and shipped medication non-refundable | Cancel 2+ days before billing; first month and shipped medication non-refundable | Cancel 48+ hours before renewal | Cancel anytime; fees non-refundable, partial refunds possible on prepaid plans |
| Public Company | Yes (NYSE: HIMS) | Yes (NYSE: HIMS) | No (private) | No (private) |
| Editor Score | 4.5 / 5 | 4.4 / 5 | 4.6 / 5 | 4.2 / 5 |
What the Studies Actually Show
Pricing reflects each provider's publicly listed rates, checked October 21, 2026. Insurance acceptance varies by employer plan and pharmacy benefit manager; coverage tools do not guarantee approval. The trial results below describe the studied branded regimens and do not measure outcomes for these providers or compounded products.
| Endpoint | Hims | Hers | Ro | Found |
|---|---|---|---|---|
| Mean weight loss in pivotal branded-regimen trials1, 3 | Studied branded regimens: semaglutide 2.4 mg (STEP 1) −14.9% at 68 weeks; tirzepatide 15 mg (SURMOUNT-1) −20.9% at 72 weeks These trial results are for the branded regimens studied in STEP 1 and SURMOUNT-1; they do not measure outcomes for a provider or compounded product. | Studied branded regimens: semaglutide 2.4 mg (STEP 1) −14.9% at 68 weeks; tirzepatide 15 mg (SURMOUNT-1) −20.9% at 72 weeks | Studied branded regimens: semaglutide 2.4 mg (STEP 1) −14.9% at 68 weeks; tirzepatide 15 mg (SURMOUNT-1) −20.9% at 72 weeks | Studied branded regimens: semaglutide 2.4 mg (STEP 1) −14.9% at 68 weeks; tirzepatide 15 mg (SURMOUNT-1) −20.9% at 72 weeks |
| GI side effects (per FDA prescribing information)2 | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% |
| Cardiovascular outcomes evidence (semaglutide 2.4 mg)4 | SELECT trial: 20% MACE risk reduction in adults with established CV disease and overweight/obesity | SELECT trial: 20% MACE risk reduction | SELECT trial: 20% MACE risk reduction | SELECT trial: 20% MACE risk reduction |
| Behavioral / coaching evidence5 | Not a coaching product; medication-only model | Not a coaching product; medication-only model | Optional coaching add-on; not a core service | Coaching included on Rx path — the Diabetes Prevention Program model shows coaching plus medication outperforms medication alone for sustained weight loss |
The Verdict
If you want the broadest single-account telehealth coverage and you are male, Hims is the natural pick — GLP-1 plus ED, hair, mental health, and primary-care add-ons under one login. Hers is the equivalent for women, with menopause and sexual-wellness coverage layered on top of GLP-1.
If insurance coverage for brand-name Wegovy or Zepbound is the deciding factor, Ro offers insurance-navigation support and an in-house pharmacy backbone. Coverage depends on your plan and pharmacy benefit manager, so confirm potential coverage and out-of-pocket costs before enrolling.
If you want behavior-change coaching paired with medication, Found is the only one of the four that builds one-on-one coaching into the core subscription rather than treating it as an upsell. Its plan fee does not include GLP-1 medication, which is billed to insurance or paid separately, and prepaid plans have their own refund rules, so read the terms before committing.
Frequently Asked Questions
Hims vs Hers — are they actually different services?
Same parent company (Hims & Hers Health, NYSE: HIMS), separate audiences and formularies. Hims targets men with GLP-1, ED, hair, and mental health; Hers targets women with GLP-1, menopause, hair, skincare, and sexual wellness. Pricing structure and pharmacy infrastructure are essentially identical.
Which one is cheapest?
At our October 21, 2026 check, none of the four listed compounded GLP-1 pricing on its weight-loss page; all four charge a membership or plan fee with medication billed separately. Ro is cheapest on membership if you prepay a year ($74/month); Hims and Hers are $149/month after a $39 first month; Found's CORE plan is $129/month or about $99/month on a six-month plan. With cash-pay brand-name medication at maintenance doses (about $349 for Wegovy, $449 for Zepbound), expect roughly $420 to $600 a month all-in. If insurance covers the medication, the totals drop sharply.
How do the platforms approach insurance navigation for brand-name Wegovy or Zepbound?
Ro and Found offer dedicated insurance-navigation support. Hims and Hers offer more limited assistance. Coverage and eligibility depend on your plan and pharmacy benefit manager, and no platform can guarantee approval.
Which one offers the broadest formulary beyond GLP-1?
Found is the most narrow (GLP-1 plus a small set of off-label oral adjuncts). Ro covers GLP-1, ED, hair loss, and primary care. Hims and Hers each offer the widest set within their respective audience (men's vs women's health), spanning four to five categories.
What should I know about compounded GLP-1s on these platforms?
Compounded products are not FDA-approved. Availability and prescribing decisions can change, so ask the provider and a licensed clinician about the product offered, the dispensing pharmacy, and whether it is appropriate for you.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- Diabetes Prevention Program (DPP) — NEJM 2002 / 10-year follow-up Lancet 2009 · Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.